Medical management of primary pulmonary hypertension

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 2, 2002, Pages 159-165

  McLaughlin, Valerie V ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Calcium channel blockers; Endothelin receptor antagonists; Primary pulmonary hypertension; Prostacyclin; Pulmonary arterial hypertension

Indexed keywords

ADENOSINE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; ILOPROST; NEUROHORMONE; NIFEDIPINE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYGEN; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; TACLEER; UNCLASSIFIED DRUG; UNIPROST; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VERAPAMIL; WARFARIN;

CATHETER INFECTION; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ERYTHEMA; FLUSHING; HEADACHE; HEART RIGHT VENTRICLE FAILURE; HUMAN; LIVER DISEASE; LUNG BLOOD VESSEL; NAUSEA; PULMONARY HYPERTENSION; REVIEW; STOMACH DISEASE; SURVIVAL RATE; SYNCOPE; THORAX PAIN; THROMBOCYTOPENIA; WEIGHT REDUCTION;

CALCIUM CHANNEL BLOCKERS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036166760     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.2.159     Document Type: Review

References (26)

1. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
2. Primary pulmonary hypertension
3. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
4. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
5. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
6. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry
7. Survival in primary pulmonary hypertension. Validation of a prognostic equation
8. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension
9. Primary pulmonary hypertension: Natural history and the importance of thrombosis
10. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
11. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
12. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension
13. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol)
14. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
15. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
16. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
17. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
18. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series
19. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
20. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
21. Efficacy and safety of UT-15, a prostacyclin analog for primary pulmonary hypertension
22. Efficacy and safety of chronic subcutaneous infusion of UT-15 in pulmonary arterial hypertension (PAH)
23. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
24. Long-term treatment of primary pulmonary hypertension with aerosolised iloprost, a prostacyclin analogue
25. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension
26. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study